🚀 VC round data is live in beta, check it out!
Argenica Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Argenica Therapeutics and similar public comparables like IRLAB Therapeutics, Quantum BioPharma, Xbrane Biopharma, Abera Bioscience and more.
Argenica Therapeutics Overview
About Argenica Therapeutics
Argenica Therapeutics Ltd is engaged in the research and development of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and its non-clinical studies to other indications and regulatory consultants.
Founded
2019
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$10M
Argenica Therapeutics Financials
Argenica Therapeutics reported last 12-month revenue of $15M and EBITDA of $11M.
In the same LTM period, Argenica Therapeutics generated $11M in EBITDA and $6M in net income.
Revenue (LTM)
Argenica Therapeutics P&L
In the most recent fiscal year, Argenica Therapeutics reported revenue of — and net income of —.
Argenica Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $15M | XXX | — | XXX | XXX | XXX |
| EBITDA | $11M | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | 72% | XXX | — | XXX | XXX | XXX |
| EBIT Margin | 72% | XXX | — | XXX | XXX | XXX |
| Net Profit | $6M | XXX | — | XXX | XXX | XXX |
| Net Margin | 39% | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Argenica Therapeutics Stock Performance
Argenica Therapeutics has current market cap of $14M, and enterprise value of $10M.
Market Cap Evolution
Argenica Therapeutics' stock price is $0.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10M | $14M | -39.0% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArgenica Therapeutics Valuation Multiples
Argenica Therapeutics trades at 0.7x EV/Revenue multiple, and 0.9x EV/EBITDA.
EV / Revenue (LTM)
Argenica Therapeutics Financial Valuation Multiples
As of April 8, 2026, Argenica Therapeutics has market cap of $14M and EV of $10M.
Equity research analysts estimate Argenica Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Argenica Therapeutics has a P/E ratio of 2.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $14M | XXX | $14M | XXX | XXX | XXX |
| EV (current) | $10M | XXX | $10M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | 0.9x | XXX | — | XXX | XXX | XXX |
| EV/EBIT | 0.9x | XXX | — | XXX | XXX | XXX |
| P/E | 2.3x | XXX | — | XXX | XXX | XXX |
| EV/FCF | 2.1x | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Argenica Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Argenica Therapeutics Margins & Growth Rates
Argenica Therapeutics' revenue in the last 12 month declined by (56%).
Argenica Therapeutics' rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Argenica Therapeutics' rule of X is 50% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Argenica Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (56%) | XXX | 340% | XXX | XXX | XXX |
| EBITDA Margin | 72% | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (111%) | XXX | (221%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 50% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Argenica Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| IRLAB Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Quantum BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Xbrane Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Abera Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Active Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Argenica Therapeutics M&A Activity
Argenica Therapeutics acquired XXX companies to date.
Last acquisition by Argenica Therapeutics was on XXXXXXXX, XXXXX. Argenica Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Argenica Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialArgenica Therapeutics Investment Activity
Argenica Therapeutics invested in XXX companies to date.
Argenica Therapeutics made its latest investment on XXXXXXXX, XXXXX. Argenica Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Argenica Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Argenica Therapeutics
| When was Argenica Therapeutics founded? | Argenica Therapeutics was founded in 2019. |
| Where is Argenica Therapeutics headquartered? | Argenica Therapeutics is headquartered in Australia. |
| Is Argenica Therapeutics publicly listed? | Yes, Argenica Therapeutics is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Argenica Therapeutics? | Argenica Therapeutics trades under AGN ticker. |
| When did Argenica Therapeutics go public? | Argenica Therapeutics went public in 2021. |
| Who are competitors of Argenica Therapeutics? | Argenica Therapeutics main competitors are IRLAB Therapeutics, Quantum BioPharma, Xbrane Biopharma, Abera Bioscience. |
| What is the current market cap of Argenica Therapeutics? | Argenica Therapeutics' current market cap is $14M. |
| What is the current revenue of Argenica Therapeutics? | Argenica Therapeutics' last 12 months revenue is $15M. |
| What is the current revenue growth of Argenica Therapeutics? | Argenica Therapeutics revenue growth (NTM/LTM) is (56%). |
| What is the current EV/Revenue multiple of Argenica Therapeutics? | Current revenue multiple of Argenica Therapeutics is 0.7x. |
| Is Argenica Therapeutics profitable? | Yes, Argenica Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Argenica Therapeutics? | Argenica Therapeutics' last 12 months EBITDA is $11M. |
| What is Argenica Therapeutics' EBITDA margin? | Argenica Therapeutics' last 12 months EBITDA margin is 72%. |
| What is the current EV/EBITDA multiple of Argenica Therapeutics? | Current EBITDA multiple of Argenica Therapeutics is 0.9x. |
| What is the current FCF of Argenica Therapeutics? | Argenica Therapeutics' last 12 months FCF is $5M. |
| What is Argenica Therapeutics' FCF margin? | Argenica Therapeutics' last 12 months FCF margin is 33%. |
| What is the current EV/FCF multiple of Argenica Therapeutics? | Current FCF multiple of Argenica Therapeutics is 2.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.